



# Core Project R03OD030604







## Details







Projects	Name	Award	Publications	Repositories	Analytics
1R03OD030604-01	Using Common Fund data to inform rare disease preclinical models and prioritize drug repurposing	\$297,000.00	9 publications	0 repositories	0 properties

## Publications

Published works associated with this project.

ID	Title	Authors	R C R	SJ R	Cita tion s	Cit./ yea r	Journal	Publ ishe d	Updat ed
<a href="#">35337371</a>  <a href="#">DOI</a> 	Considerations and challenges for sex-aware drug repurposing.	Jennifer L Fisher	1. 46	2. 03	9	4.5	Biology of Sex Differences	2,022	Oct 26,

		...4 more... Brittany N Lasseigne							2024 (1 mont h ago)
<a href="#">37533331</a>  <a href="#">DOI</a> 	Evaluating cancer cell line and patient-derived xenograft recapitulation of tumor and non-disease...	Avery S Williams ...2 more... Brittany N Lasseigne	1. 05	0	3	3	Cancer Rep (Hoboken)	2,023	Oct 26, 2024 (1 mont h ago)
<a href="#">36602970</a>  <a href="#">DOI</a> 	Ten simple rules for using public biological data for your research.	Vishal H Oza ...9 more... Brittany N Lasseigne	0. 61	1. 65 2	2	2	PLoS Computational Biology	2,023	Oct 26, 2024 (1 mont h ago)
<a href="#">37824797</a>  <a href="#">DOI</a> 	Computational Advancements in Cancer Combination Therapy Prediction.	Victoria L Flanary ...3 more... Brittany	0. 46	2. 24 9	2	2	JCO Precision Oncology	2,023	Oct 26, 2024 (1


		N Lasseign e								mont h ago)
<a href="#">37217845</a>  <a href="#">DOI</a> 	Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and...	Elizabet h J Wilk ...9 more... Brittany N Lasseign e	0. 39	1. 44 6	1	1	Molecular Medicine	2,02 3	Nov 8, 2024 (2 weeks ago)	
<a href="#">37090499</a>  <a href="#">DOI</a> 	Evaluating cancer cell line and patient-derived xenograft recapitulation of tumor and non-disease...	Avery S Williams ...2 more... Brittany N Lasseign e	0	0	0	0	bioRxiv	2,02 3	Oct 26, 2024 (1 mont h ago)	
<a href="#">37362157</a>  <a href="#">DOI</a> 	Sex-biased gene expression and gene-regulatory networks of sex-biased adverse event drug targets ...	Jennifer L Fisher ...2 more... Brittany N Lasseign e	0	0	0	0	bioRxiv	2,02 3	Oct 26, 2024 (1 mont h ago)	

<a href="#">38167211</a>  <a href="#">DOI</a> 	Sex-biased gene expression and gene-regulatory networks of sex-biased adverse event drug targets ...	Jennifer L Fisher ...2 more... Brittany N Lasseigne	0	0.71	0	0	BMC pharmacology & toxicology	2,024	Oct 26, 2024 (1 month ago)
<a href="#">38531616</a>  <a href="#">DOI</a> 	Signature reversion of three disease-associated gene signatures prioritizes cancer drug repurposi...	Jennifer L Fisher ...7 more... Brittany N Lasseigne	0	0.789	0	0	FEBS Open Bio	2,024	Oct 26, 2024 (1 month ago)

Notes

RCR    [Relative Citation Ratio](#) 

SJR    [Scimago Journal Rank](#) 



## Analytics

Traffic metrics of websites associated with this project.

### Notes

Active Users      [Distinct users who visited the website](#) .

New Users      [Users who visited the website for the first time](#) .

Engaged Sessions      [Visits that had significant interaction](#) .

"Top" metrics are measured by number of engaged sessions.

Generated on Nov 24, 2024

Developed with support from NIH Award [U54 OD036472](#)